Since the Women's Health Initiative (WHI) study, estrogen has been widely vilified, leading to fear and misconceptions about its role in health. However, estrogen itself is not inherently harmful-its metabolism and elimination determine its impact on overall well-being and breast health.
This presentation unravels the complexities of estrogen metabolism and the estrobolome, shedding light on how hormones are processed and cleared from the body. The essential role of urinary hormone and metabolite testing will be explored, offering insights into individual metabolic function. A deep dive into phase 1, 2, and 3 metabolism will provide healthcare providers and patients with practical strategies for optimizing estrogen balance through lifestyle modifications, nutrition, treatment sequencing, and targeted nutraceutical interventions.
By bridging the gap between fear and science, this presentation delivers a balanced perspective on estrogen, equipping attendees with the knowledge needed to support hormonal health with confidence.
Register here: |
| 12:00 PM PST |
As clinicians when we order a lab test, it is generally because we expect a certain result. For example, you may meet with a patient who has significant GI distress and you are relatively sure they will present with some level of pathogenic bacteria, and yet when the stool test is received, the pathogens expected are not there. This does not mean that there was not a positive finding! In this lecture we will review the inflammatory potential of the lack of a healthy microbiome, SCFA and the additional clues sIgA, lactoferrin and other markers give us. We will examine the research that shows interaction with SCFA beyond the blood brain barrier, as well as interactions with beneficial flora, brain health, cardiovascular health and general immune regulation. We will look at the significant impact that microbial deficiencies create and other patterns that emerge from stool testing beyond dysbiosis.
Register here: |
| 11:00 AM PST |
Cardiovascular disease is the leading cause of death worldwide yet is often preventable, emphasizing a need for better early screening measures. Major modifiable risk factors such as obesity, metabolic syndrome, hyperlipidemia, hypertension, poor nutrition and sedentary lifestyle are on the rise. While routine laboratory testing like fasting glucose and the lipid panel can fail to identify individuals at high risk of atherosclerosis and insulin resistance, advanced lipid testing and more modern metabolic and inflammatory lab markers can more precisely distinguish high risk patients for whom lifestyle changes and medications could increase lifespan and enhance the proportion of time spent in good health.
Through patient cases, we will discover how assessing levels of oxidized LDL-C, small dense LDL-C, non-HDL-C and apolipoprotein B provides a clearer representation of cardiovascular health than standard markers like LDL-C. Find early evidence of adverse metabolic health with leptin and 1,5-anhydroglucitol. Lastly, we will uncover how fad diets like ketogenic truly impact health. Learn to interpret precision cardiometabolic biomarkers and help patients gain control of their health today.
Register here: |
| 12:00 PM PST |
Join us for Fullscript Forward, a free, live, virtual event featuring industry leaders driving the future of healthcare and the field of whole person care.
This presentation explores the pathophysiology of breast cancer risk in menopause and introduces the HuMap™, a non-invasive tool for assessing urinary hormones and their metabolites. This presentation will explore phase I and phase II estrogen metabolism, emphasizing the significance of urinary hormone and metabolite testing for uncovering an individual's unique metabolic function. Assessing estrogen metabolite imbalance is a reasonable first step to developing an effective risk reduction strategy for these patients.
Register here: |
| 11:05 AM PST |